Gallipoli et al. concluded that the JAK2/STAT5 signaling pathway is an important therapeutic target in CML stem/progenitor cells, and that JAK2/STAT5 inhibition by nilotinib and ruxolitinib might contribute to obtain disease eradication [12]. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.